Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis

European Urology

Volumn 48, Issue 3, 2005, Pages 386-399

  Roddam, Andrew W ^a   Duffy, Michael J ^b   Hamdy, Freddie C ^c   Ward, Anthony Milford ^c   Patnick, Julietta ^d   Price, Christopher P ^e,f   Rimmer, Janet ^d   Sturgeon, Cathie ^g   White, Peter ^h   Allen, Naomi E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d NATIONAL HEALTH SERVICE   (United Kingdom)

^e Bayer plc UK   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^h UK NEQAS for Immunochemistry and Immunology   (United Kingdom)

Author keywords

Complex PSA; Diagnostic accuracy; Early detection; Free PSA; Prostate cancer; Prostate specific antigen; PSA; Reflex tests; Sensitivity; Specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; EARLY DIAGNOSIS; HUMAN; MALE; META ANALYSIS; OBSERVER VARIATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW;

EID: 23944492852     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.04.015     Document Type: Review

References (106)

1. J. Ferlay, F. Bray, P. Pisani, and D.M. Parkin Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide Version 1.0. 2001 IARC Press Lyon http://www.iarc.fr/globocan/globocan.html (accessed June 2003)
2. R. Nadler, P. Humphrey, D. Smith, W. Catalona, and T. Ratliff Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate-specific antigen levels J Urol 154 1995 407 413
3. W.J. Catalona, D.S. Smith, T.L. Ratliff, K.M. Dodds, D.E. Coplen, and J.J. Yuan Measurement of prostate-specific antigen in serum as a screening test for prostate cancer New Engl J Med 324 1991 1156 1161
4. W.J. Catalona, J.P. Richie, F.R. Ahmann, M.A. Hudson, P.T. Scardino, and R.C. Flanigan Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men J Urol 151 1994 1283 1290
5. M.K. Brawer, C.D. Cheli, I.E. Neaman, J. Goldblatt, C. Smith, and M.K. Schwartz Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer J Urol 163 2000 1476 1480
6. 1-protease inhibitor for screening prostate cancer J Urol 164 2000 1956 1960
7. G.L. Andriole, D.L. Levin, E.D. Crawford, E.P. Gelmann, P.F. Pinsky, D. Chia for the PLCO Project Team Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial JNCI Cancer Spectrum 97 2005 433 438
8. K. Mistry, and G. Cable Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma J Am Board Fam Pract 16 2003 95 101
9. I.M. Thompson, D.K. Pauler, P.J. Goodman, C.M. Tangen, M.S. Lucia, and H.L. Parnes Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng/ml New Engl J Med 350 2004 2239 2246
10. F.H. Schroder, I. van der Cruijsen-Koeter, H.J. de Koning, A.N. Vis, R.F. Hoedemaeker, and R. Kranse Prostate cancer detection at low prostate specific antigen J Urol 163 2000 806 812
11. W.J. Catalona, C.G. Ramos, G.F. Carvalhal, and Y. Yan Lowering PSA cutoffs to enhance detection of curable prostate cancer Urology 55 2000 791 795
12. R. Etzioni, D.F. Penson, J.M. Legler, D. di Tommaso, R. Boer, and P.H. Gann Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 2002 981 990
13. P.H. Gann, C.H. Hennekens, and M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 1995 289 294
14. M.K. Brawer, M.P. Chetner, J. Beatie, D.M. Buchner, R.L. Vessella, and P.H. Lange Screening for prostatic-carcinoma with prostate specific antigen J Urol 147 1992 841 845
15. S.G. Baker The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer J Natl Cancer Inst 95 2003 511 515
16. L. Moses, D. Shapiro, and B. Littenberg Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations Stats Med 12 1993 1293 1316
17. K. Liang, and S. Zeger Longitudinal data analysis using generalized linear models Biometrika 73 1986 13 22
18. S. Zeger, and K. Liang Longitudinal data analysis for discrete and continuous outcomes Biometrics 42 1986 121 130
19. J. Lijmer, P. Bossuyt, and S. Heisterkamp Exploring source of heterogeneity in systematic reviews of diagnostic tests Stats Med 21 2002 1525 1537
20. R Development Core Team R: A Language and Environment for Statistical Computing 2004 Austria R Foundation for Statistical Computing Vienna
21. M.K. Brawer, G.E. Meyer, J.L. Letran, D.D. Bankson, D.L. Morris, and K.K. Yeung Measurement of complexed PSA improves specificity for early detection of prostate cancer Urology 52 1998 372 378
22. W.J. Catalona, A.W. Partin, K.M. Slawin, C.K. Naughton, M.K. Brawer, and R.C. Flanigan Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial Urology 55 2000 372 376
23. W.J. Catalona, D.S. Smith, and D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements JAMA 277 1997 1452 1455
24. K.A. Roehl, J.A. Antenor, and W.J. Catalona Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/ml range J Urol 168 2002 922 925
25. B. Djavan, A. Zlotta, C. Kratzik, M. Remzi, C. Seitz, and C.C. Schulman PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml Urology 54 1999 517 522
26. W.J. Catalona, A.W. Partin, J.A. Finlay, D.W. Chan, H.G. Rittenhouse, and R.L. Wolfert Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model Urology 54 1999 220 224
27. A.W. Partin, W.J. Catalona, J.A. Finlay, C. Darte, D.J. Tindall, and C.Y. Young Use of human glandular kallikrein-2 for the detection of prostate cancer: preliminary analysis Urology 54 1999 839 845
28. S. Egawa, S. Soh, M. Ohori, T. Uchida, K. Gohji, and A. Fujii The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan Cancer 79 1997 90 98
29. A. Magklara, A. Scorilas, W.J. Catalona, and E.P. Diamandis The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA Clin Chem 45 1999 1960 1966
30. A. Reissigl, H. Klocker, J. Pointner, K. Fink, W. Horninger, and O. Ennemoser Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening Urology 48 1996 62 66
31. F.B. Trinkler, D.M. Schmid, D. Hauri, P. Pei, F.E. Maly, and T. Sulser Free/total prostate-specific antigen ratio can prevent unnecessary prostate biopsies Urology 52 1998 479 486
32. C. Mettlin, A.E. Chesley, G.P. Murphy, G. Bartsch, A. Toi, and R. Bahnson Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer Prostate 39 1999 153 158
33. H.J. Luboldt, A. Swoboda, C. Borgermann, P. Fornara, and H. Rubben Clinical usefulness of free PSA in early detection of prostate cancer Onkologie 24 2001 33 37
34. C.H. Bangma, R. Kranse, B.G. Blijenberg, and F.H. Schroder The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men Urology 46 1995 773 778
35. W.J. Catalona, D.S. Smith, R.L. Wolfert, T.J. Wang, H.G. Rittenhouse, and T.L. Ratliff Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening JAMA 274 1995 1214 1220
36. W.J. Catalona, A.W. Partin, K.M. Slawin, M.K. Brawer, R.C. Flanigan, and A. Patel Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial JAMA 279 1998 1542 1547
37. R.L. Vessella, P.H. Lange, A.W. Partin, D.W. Chan, L.J. Sokoll, and E.A. Sasse Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays Urology 55 2000 909 914
38. C. Dincel, T. Caskurlu, A.I. Tasci, M. Cek, G. Sevin, and A. Fazlioglu Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels Int Urol Nephrol 31 1999 497 509
39. F. Recker, M.K. Kwiatkowski, T. Piironen, K. Pettersson, M. Goepel, and R. Tscholl Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels Br J Urol 81 1998 532 538
40. A.W. Partin, W.J. Catalona, P.C. Southwick, E.N. Subong, G.H. Gasior, and D.W. Chan Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age Urology 48 1996 55 61
41. L. Martinez-Pineiro, A. Tabernero, T. Contreras, R. Madero, D. Lozano, and J. Lopez-Tello Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml Eur Urol 37 2000 289 296
42. J. Morote, C.X. Raventos, J.A. Lorente, M.A. Lopez-Pacios, G.d.e.T.I. Encabo, and J. Andreu Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml J Urol 158 1997 502 504
43. F. Espana, M. Royo, M. Martinez, M.J. Enguidanos, C.D. Vera, and A. Estelles Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples J Urol 160 1998 2081 2088
44. B. Djavan, M. Remzi, A.R. Zlotta, C. Seitz, R. Wolfram, and S. Hruby Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction Tech Urol 5 1999 71 76
45. H. Ozen, C. Aygun, A. Ergen, S. Sozen, F.T. Aki, and M.C. Uygur Combined use of prostate-specific antigen derivatives decreases the number of unnecessary biopsies to detect prostate cancer Am J Clin Oncol 24 2001 610 613
46. S. Lieberman Can percent free prostate-specific antigen reduce the need for prostate biopsy? Eff Clin Pract 2 1999 266 271
47. G. Alivizatos, C. Deliveliotis, D. Mitropoulos, G. Raptides, G. Louras, and A. Karayiannis Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy? Urology 48 1996 71 75
48. H. Maeda, Y. Arai, K. Okubo, Y. Aoki, T. Okada, and S. Maekawa Value of the free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients Int J Urol 5 1998 343 348
49. H. Matsuyama, Y. Baba, G. Yamakawa, N. Yamamoto, and K. Naito Diagnostic value of prostate-specific antigen-related parameters in discriminating prostate cancer Int J Urol 7 2000 409 414
50. S. Egawa, K. Suyama, K. Matsumoto, S. Kuwao, and S. Baba Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples J Urol 167 2002 97 102
51. A. Reissigl, H. Klocker, J. Pointner, O. Ennemoser, M. Falk, and G. Bartsch Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels Prostate 30 1997 243 247
52. C.H. Bangma, J.B. Rietbergen, R. Kranse, B.G. Blijenberg, K. Petterson, and F.H. Schroder The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population J Urol 157 1997 2191 2196
53. M. Vogl, M.M. Muller, and W. Holtl Clinical usefulness of percentage of free serum prostate specific antigen Clin Chim Acta 258 1997 79 90
54. B. Djavan, M. Remzi, A.R. Zlotta, V. Ravery, P. Hammerer, and A. Reissigl Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial Urology 60 2002 4 9
55. M.C. Miller, G.J. O'Dowd, A.W. Partin, and R.W. Veltri Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics Urology 57 2001 1105 1111
56. K. Okihara, H.A. Fritsche, A. Ayala, D.A. Johnston, W.J. Allard, and R.J. Babaian Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml J Urol 165 2001 1930 1936
57. A. Haese, R.T. Dworschack, and A.W. Partin Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng/ml range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng/ml range J Urol 168 2002 504 508
58. J.E.J. Fowler, J. Sanders, S.A. Bigler, J. Rigdon, N.K. Kilambi, and S.A. Land Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng/ml J Urol 163 2000 1467 1470
59. A.F. Prestigiacomo, and T.A. Stamey Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol 157 1997 189 194
60. K. Okihara, C.D. Cheli, A.W. Partin, H.A. Fritsche, D.W. Chan, and L.J. Sokoll Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer J Urol 167 2002 2017 2023
61. 1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/ml: comparison with PSA-related parameters Int J Urol 8 2001 589 593
62. T. Okegawa, H. Noda, K. Nutahara, and E. Higashihara Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer Eur Urol 38 2000 380 387
63. T. Okegawa, H. Noda, K. Nutahara, and E. Higashihara Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/ml Urology 55 2000 700 704
64. T. Okegawa, M. Kinjo, K. Watanabe, H. Noda, M. Kato, and A. Miyata The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/ml Br J Urol Int 85 2000 708 714
65. T. Saika, T. Tsushima, Y. Nasu, N. Kusaka, Y. Miyaji, and H. Takamoto Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels Cancer 94 2002 1685 1691
66. T. Kobayashi, T. Kamoto, Y. Isogawa, H. Kinoshita, A. Terai, and T. Habuchi Ratio of prostate specific antigen minor molecular forms-to-total prostate specific antigen is constant regardless of the pathological condition of the prostate J Urol 169 2003 121 124
67. D.G. Moon, J. Cheon, J.J. Kim, D.K. Yoon, and S.K. Koh Prostate-specific antigen adjusted for the transition zone volume versus free-to-total prostate-specific antigen ratio in predicting prostate cancer Int J Urol 6 1999 455 462
68. H. Maeda, Y. Arai, Y. Aoki, K. Okubo, T. Okada, and S. Maekawa Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer Urology 54 1999 225 228
69. M. Horinaga, J. Nakashima, M. Ishibashi, M. Oya, T. Ohigashi, and K. Marumo Clinical value of prostate specific antigen based parameters for the detection of prostate cancer on repeat biopsy: the usefulness of complexed prostate specific antigen adjusted for transition zone volume J Urol 168 2002 986 990
70. S. Baltaci, H. Aksoy, K. Turkolmez, A.H. Elhan, E. Ozden, and O. Gogus Use of percent free prostate-specific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostate-specific antigen levels Urol Int 70 2003 36 41
71. M. Lein, M. Kwiatkowski, A. Semjonow, H.J. Luboldt, P. Hammerer, and C. Stephan A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations J Urol 170 2003 1175 1179
72. B.J. Martin, J.A. Finlay, K. Sterling, M. Ward, D. Lifsey, and D. Mercante Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein-2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA) Proc Cancer Prostatic Dis 7 2004 132 137
73. L. Martinez-Pineiro, M.J. Garcia, G.P. Gonzalez, A. Tabernero, D. Lozano, and J.J. Lopez-Tello Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4-10 ng/ml World J Urol 22 2004 124 131
74. K. Okihara, O. Ukimura, T. Nakamura, Y. Mizutani, A. Kawauchi, and Y. Naya Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men? Eur Urol 46 2004 57 64
75. J.K. Parsons, M.K. Brawer, C.D. Cheli, A.W. Partin, and R. Djavan Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/ml range of total PSA Br J Urol Int 94 2004 47 50
76. A.W. Partin, M.K. Brawer, G. Bartsch, W. Horninger, S.S. Taneja, and H. Lepor Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial J Urol 170 2003 1787 1791
77. N. Segawa, K. Gohji, Y. Iwamoto, H. Ueda, and Y. Katsuoka Prostate cancer detection by prostate-specific antigen-related parameters Acta Urol Jpn 49 2003 405 410
78. C.O. Yeniyol, G. Bozkaya, A. Cavusoglu, M. Arslan, B. Karaca, and A.R. Ayder The relation of prostate biopsy results and ratio of free to total PSA in patients with a total PSA between 4-20 ng/ml Int Urol Nephrol 33 2001 503 506
79. I. Sakai, K. Harada, I. Hara, H. Eto, and H. Miyake Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men Int J Clin Oncol 9 2004 64 67
80. F. Labrie, B. Candas, A. Dupont, L. Cusan, J.L. Gomez, and R.E. Suburu Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial Prostate 38 1999 83 91
81. J.S. Krumholtz, G.F. Carvalhal, C.G. Ramos, D.S. Smith, P. Thorson, and Y. Yan Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features Urology 60 2002 469 473
82. D.W. Keetch, W.J. Catalona, and D.S. Smith Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values J Urol 151 1994 1571 1574
83. M.A. Levine, M. Ittman, J. Melamed, and H. Lepor Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer J Urol 159 1998 471 475
84. R.S. Punglia, A.V. D'Amico, W.J. Catalona, K.A. Roehl, and K.M. Kuntz Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen New Engl J Med 349 2003 335 342
85. L.J. Sokoll, D.J. Bruzek, R. Dua, W. Dunn, P. Mohr, and G. Wallerson Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen Urology 60 2002 24 30
86. U.H. Stenman, M. Hakama, P. Knekt, A. Aromaa, L. Teppo, and J. Leinonen Serum concentrations of prostate specific antigen and its complex with alpha-1-antichymotrypsin before diagnosis of prostate cancer Lancet 344 1994 1594 1598
87. D. Woodrum, C. French, and L.B. Shamel Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions Urology 48 1996 33 39
88. M.H. Wener, P.R. Daum, and M.K. Brawer Variation in measurement of prostate-specific antigen: importance of method and lot variability Clin Chem 41 1995 1730 1737
89. A.M. Zhou, P.C. Tewari, B.I. Bluestein, G.W. Caldwell, and F.L. Larsen Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays Clin Chem 39 1993 2483 2491
90. A. Semjonow, F. Oberpenning, C. Weining, M. Schon, B. Brandt, and G. De Angelis Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer? Clin Chem 47 2001 1472 1475
91. J.E. Busby, and C.P. Evans Determining variables for repeat prostate biopsy Proc Cancer Prostatic Dis 7 2004 93 98
92. D. Basso, P. Fogar, M.G. Piva, F. Navaglia, S. Mazza, and T. Prayer-Galetti Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? Urologyt 55 2000 710 715
93. O.L. Ozdal, A.G. Aprikian, L.R. Begin, H. Behlouli, and S. Tanguay Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer Br J Urol Int 93 2004 970 974
94. L. Holmberg, A. Bill-Axelson, F. Helgesen, J.O. Salo, P. Folmerz, and M. Haggman A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer New Engl J Med 347 2002 781 789
95. H.J. De Koning, M.K. Liem, C.A. Baan, R. Boer, F.H. Schröder, and F.E. Alexander Prostate cancer mortality reduction by screening: power and time frame with complete enrolment in the European Randomised Screening for Prostate Cancer (ERSPC) trial Int J Cancer 98 2002 268 273
96. J.K. Gohagan, P.C. Prorok, B.S. Kramer, and J.E. Cornett Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute J Urol 152 1994 1905 1909
97. U.H. Stenman, J. Leinonen, H. Alfthan, S. Rannikko, K. Tuhkanen, and O. Alfthan A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Res 51 1991 222 226
98. A. Roddam, M. Duffy, F. Hamdy, A. Milford Ward, J. Patnick, and C. Price Use of PSA isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis Eur Urol 2005 this issue
99. 1- antichymotrypsin Clin Chem 39 1993 2098 2103
100. 1-antichymotrypsin complex together with free or total PSA Clin Chem 49 2003 97 103
101. G. Draisma, R. Boer, S.J. Otto, I.W. Van der Cruijsen, R.A. Damhuis, and F.H. Schröder Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
102. A.V. D'Amico, M.H. Chen, K.A. Roehl, and W.J. Catalona Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy New Engl J Med 351 2004 125 135
103. W.A. Sakr, D.J. Grignon, J.D. Crissman, L.K. Heilbrun, B.J. Cassin, and J.J. Pontes High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases In Vivo 8 1994 439 443
104. J. Hugosson, G. Aus, H. Lilja, P. Lodding, and C.G. Pihl Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma Cancer 100 2004 1397 1405
105. P.C. Southwick, W.J. Catalona, A.W. Partin, K.M. Slawin, M.K. Brawer, and R.C. Flanigan Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial J Urol 162 1999 1346 1351
106. P. Finne, A. Auvinen, J. Aro, H. Juusela, L. Määttänen, and S. Rannikko Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination Eur Urol 41 2002 619 627